Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • Meetings
    • Press Releases
    • Publications
  • Contact

Archives

Monthly Archive for: "Dicembre, 2019"
Home » Archivi per Dicembre 2019
0

Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!